<i>In vivo</i> treatment decreases bacterial burden and colonization of vital organs in a skin abscess biofilm infection model. by Robert L. Beckman I.V (22784303)

Decomposition analysis of gastric cancer burden in Taiwan, stratified by gender. (A) Incidence. (B) Prevalence. (C) Mortality. (D) DALYs. Positive values on the X-axis indicate an... by Xiaohuang Yang (10182727)

Subjects:

Summary of study eligibility criteria. by Biban Gill (1473337)

“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”

Summary of study participation and feasibility. by Biban Gill (1473337)

“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”

Baseline characteristics of participants for changes in frailty status analyses. by Xiaohan Gan (22097061)

Subjects:

Association of changes in frailty status with risks of Urinary Incontinence. by Xiaohan Gan (22097061)

Subjects:

Changes in gut microbial taxa (Genus level)pre- and post-surgery. by Manal Ali Ahmad (16868808)

Subjects:

Demographics, anthropometrics, and biochemical parameters between pre- and post-bariatric surgery (n = 19). by Manal Ali Ahmad (16868808)

Subjects:

Flowchart of sample selection. by Xiaohan Gan (22097061)

Subjects:

Baseline characteristics of participants for baseline frailty status analyses. by Xiaohan Gan (22097061)

Subjects:

Boxplots display the median (as the central tendency) and the interquartile range (25th to 75th percentiles) as the bottom and top edges of the box. by Manal Ali Ahmad (16868808)

Subjects:

Principal Coordinate Analysis (PCoA) based on (A) Unweighted UniFrac, (B) Weighted UniFrac, (C) Bray-Curtis dissimilarity, and (D) Jaccard similarity. by Manal Ali Ahmad (16868808)

Subjects:

α-diversity pre- and post-SG-surgery. by Manal Ali Ahmad (16868808)

Subjects:

Comparison of gut microbial composition at the phylum level pre- and post-surgery. by Manal Ali Ahmad (16868808)

Subjects:

Association of frailty status with risks of Urinary Incontinence. by Xiaohan Gan (22097061)

Subjects:

Subgroup analyses for the association of frailty status with risks of Urinary Incontinence by potential mediators. by Xiaohan Gan (22097061)

Subjects:

Prevalence of the common NCD risk factors by region. by Ronald Kusolo (13200268)

Subjects:

Prevalence of the common NCD risk factors by Urbanicity. by Ronald Kusolo (13200268)

Subjects:

Participant characteristics. by Ronald Kusolo (13200268)

Subjects:

Uganda 2023 NCD risk factor STEPS survey data. by Ronald Kusolo (13200268)

Subjects: